Stock COH COCHLEAR LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Cochlear Limited Stock

Equities

COH

AU000000COH5

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E.
Other stock markets
 02:10:45 2024-04-19 am EDT 		5-day change 1st Jan Change
315.6 AUD -1.02% Intraday chart for Cochlear Limited -1.67% +5.69%
05:43pm Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old CI
Apr. 04 Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business MT

Financials

Sales 2024 * 2.28B 1.46B Sales 2025 * 2.5B 1.6B Capitalization 20.67B 13.27B
Net income 2024 * 392M 252M Net income 2025 * 444M 285M EV / Sales 2024 * 8.85 x
Net cash position 2024 * 523M 336M Net cash position 2025 * 580M 372M EV / Sales 2025 * 8.05 x
P/E ratio 2024 *
52.8 x
P/E ratio 2025 *
47.1 x
Employees 4,800
Yield 2024 *
1.32%
Yield 2025 *
1.51%
Free-Float 99.37%
More Fundamentals * Assessed data

Chart Cochlear Limited

Dynamic Chart

Latest news about Cochlear Limited

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old CI
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business MT
Miners, healthcare firms push Australia stocks higher RE
Sensorion: study results in hearing loss CF
Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight MT
Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral MT
Cochlear's Revenue Soars on Sales Growth MT
Australian Shares Flat as Mining, Financials Rally Offset Other Sectors' Losses MT
Cochlear Shares Slip 2%; Expects 26% Rise in Full Year Net Profit After Increase in H1 FY24 Profit, Revenue MT
Transcript : Cochlear Limited, H1 2024 Earnings Call, Feb 19, 2024
Cochlear Posts Rise in H1 FY24 Profit, Revenue MT
Correction: --Cochlear Reports Half Year FY24 Revenue Up 24% to AU$1.1 Billion; EPS of AU$2.913 MT
Cochlear Reports Half Year FY24 Revenue Up Down 24% to AU$1.1 Billion; EPS of AU$2.913 MT
Tranche Update on Cochlear Limited's Equity Buyback Plan announced on February 15, 2023. CI
Cochlear Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
More news

Latest transcript on Cochlear Limited

Logo Cochlear Limited
Cochlear Limited, H1 2024 Earnings Call, Feb 19, 2024
More transcripts

Analyst Recommendations on Cochlear Limited

Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight MT
Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral MT
Australian shares post first weekly fall in three as rate-hike bets back in focus RE
Jarden Research Adjusts Cochlear's Price Target to AU$237.17 From AU$229.20, Keeps at Neutral MT
FTSE 100 Closes Down 0.75% After Rate Hike; Ocado Surges on Bid Speculation DJ
More recommendations

Press releases Cochlear Limited

ACCC will not oppose revised Cochlear, Oticon Medical transaction AQ
Sensorion Reports 2023 First Half Results AQ
Cochlear : 2023 Annual / Sustainability Report PU
Cochlear : 2023 Tax Contribution Report PU
Cochlear : 2023 Corporate Governance Statement PU
More press releases

News in other languages on Cochlear Limited

Sensorion : résultats d'une étude dans la perte auditive
Sensorion: fin du recrutement pour l'essai clinique de Sens-401
MÄRKTE ASIEN/Börsen in China von mauer Konjunktur gebremst - Tokio erholt
Meer verlies en minder omzet bij Nyxoah
Nyxoah haalt bijna 3 miljoen dollar op
More news

Quotes and Performance

1 day-1.02%
1 week-1.67%
Current month-6.48%
1 month-5.12%
3 months+9.01%
6 months+23.54%
Current year+5.69%
More quotes

Highs and lows

1 week
311.06
Extreme 311.06
320.99
1 month
311.06
Extreme 311.06
342.40
Current year
283.70
Extreme 283.7
350.17
1 year
220.40
Extreme 220.4
350.17
3 years
178.55
Extreme 178.545
350.17
5 years
154.60
Extreme 154.6
350.17
10 years
56.96
Extreme 56.96
350.17
More quotes

Managers and Directors - Cochlear Limited

Managers TitleAgeSince
Diggory Howitt CEO
 Chief Executive Officer - 99-12-31
Catriona Deans CHM
 Chairman 56 15-01-31
Stuart Sayers DFI
 Director of Finance/CFO - 16-04-30
Members of the board TitleAgeSince
Michael Daniell BRD
 Director/Board Member 66 19-12-31
Glen Boreham BRD
 Director/Board Member 60 14-12-31
Christine McLoughlin BRD
 Director/Board Member 60 20-10-31
More insiders

ETFs positioned on Cochlear Limited

Name Weight AuM 1st Jan change Investor Rating
HAN-GINS INDXX HEALTHCARE MEGATREND EQUAL WEIGHT UCITS ETF - ACC - USD ETF HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF - Acc - USD
1.14% 16 M€ -9.75%
BETASHARES AUSTRALIAN DIVIDEND HARVESTER FUND (MANAGED FUND) - AUD ETF BetaShares Australian Dividend Harvester Fund (Managed Fund) - AUD
0.69% 121 M€ -0.87% -
RBC QUANT EAFE EQUITY LEADERS ETF - USD ETF RBC Quant EAFE Equity Leaders ETF - USD
0.35% 2 M€ +9.19% -
More ETFs positioned on Cochlear Limited

Quotes

Date Price Change Volume
24-04-19 315.6 -1.02% 118 900
24-04-18 318.9 +0.20% 96,002
24-04-17 318.2 +1.10% 98,774
24-04-16 314.8 -1.13% 197,350
24-04-15 318.4 -0.52% 81,019

Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT

More quotes

Company Profile

Cochlear Limited is an Australia-based company, which provides implantable hearing solutions and sound processors. The Company is engaged in development, manufacture and commercialization of implantable hearing solutions. Its segments include Cochlear implants, Services (sound processor upgrades and other) and Acoustics. The Company’s products and services portfolio include Cochlear implant portfolio, Acoustic solutions portfolio, and Recipient support tools. Its Cochlear Connected Care solutions include Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Link, Cochlear Remote Assist, and Cochlear Remote Check solution for cochlear implants. Its Cochlear implant portfolio include Cochlear Nucleus System. Its Acoustic solutions portfolio include Cochlear Osia System, and Cochlear Baha System. Its Recipient support tools include Cochlear Nucleus, Baha and Osia Smart Apps and Cochlear CoPilot App.
Sector
Medical Equipment, Supplies & Distribution
Calendar
2024-08-14 - Q4 2024 Earnings Release
Related indices
S&P/ASX 200
More about the company

Income Statement Evolution

More financial data

Ratings for Cochlear Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
16
Last Close Price
315.6 AUD
Average target price
280.9 AUD
Spread / Average Target
-11.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

1st Jan change Capi.
COCHLEAR LIMITED Stock Cochlear Limited
+5.69% 13.45B
STRAUMANN HOLDING AG Stock Straumann Holding AG
-1.84% 23.52B
SONOVA HOLDING AG Stock Sonova Holding AG
-9.62% 16.27B
DEMANT A/S Stock Demant A/S
+6.62% 9.68B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Stock Eyebright Medical Technology (Beijing) Co., Ltd.
-21.76% 2.01B
EMBLA MEDICAL HF. Stock Embla Medical hf.
+12.20% 1.8B
ANGELALIGN TECHNOLOGY INC. Stock Angelalign Technology Inc.
+30.15% 1.62B
MODERN DENTAL GROUP LIMITED Stock Modern Dental Group Limited
+8.37% 570M
ANGEL ROBOTICS CO., LTD. Stock Angel Robotics Co., Ltd.
0.00% 524M
INTEGRUM AB Stock Integrum AB
+29.68% 96.53M
Medical Prosthetics
  1. Stock Market
  2. Equities
  3. COH Stock